

# Martin Christian Michel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9173943/publications.pdf>

Version: 2024-02-01

295  
papers

12,183  
citations

31976

53  
h-index

37204

96  
g-index

319  
all docs

319  
docs citations

319  
times ranked

11420  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of Fenoterol to Study $\beta_2$ -Adrenoceptor Function in the Rat Urinary Bladder. <i>Pharmacology</i> , 2022, 107, 116-121.	2.2	5
2	Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient Benefit. <i>Biomedicines</i> , 2022, 10, 270.	3.2	3
3	Does coupling to ADP ribosylation factor 6 explain differences between muscarinic and other receptors in interaction with $\beta_2$ -adrenoceptor-mediated smooth muscle relaxation?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 381-386.	3.0	1
4	What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine. <i>Advances in Therapy</i> , 2022, 39, 2489-2501.	2.9	5
5	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 867-885.	3.0	12
6	Established and emerging treatments for diabetes-associated lower urinary tract dysfunction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 887-906.	3.0	10
7	Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment. <i>Neurourology and Urodynamics</i> , 2022, 41, 1399-1405.	1.5	3
8	Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2777-2789.	2.4	8
9	Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression. <i>World Journal of Urology</i> , 2021, 39, 2635-2643.	2.2	11
10	Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting. <i>Journal of Clinical Medicine</i> , 2021, 10, 311.	2.4	8
11	A teaching tool about the fickle p value and other statistical principles based on real-life data. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 1315-1319.	3.0	1
12	Medications and Drug Targets for the Treatment of Diseases of the Urinary Bladder and Urethra. , 2021, , .		0
13	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 839-852.	3.0	7
14	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 1131-1131.	0.4	0
15	21st century headache: mapping new territory. <i>Journal of Headache and Pain</i> , 2021, 22, 19.	6.0	19
16	Statistical inference in abstracts of 3 influential clinical pharmacology journals analysed using a text-mining algorithm. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4173-4182.	2.4	3
17	Function and morphology of the urinary bladder after denervation. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021, 320, R833-R834.	1.8	2
18	Effects of Nifedipine on Renal and Cardiovascular Responses to Neuropeptide Y in Anesthetized Rats. <i>Molecules</i> , 2021, 26, 4460.	3.8	1

#	ARTICLE	IF	CITATIONS
19	Re: PIEZO2 in Sensory Neurons and Urothelial Cells Coordinate Urination. <i>European Urology</i> , 2021, 80, 255-256.	1.9	0
20	Adrenoceptors in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	6
21	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2021, 178, S27-S156.	5.4	337
22	Cardiovascular, Urinary and Respiratory Pharmacology: Overview. , 2021, , .		0
23	Î²-Adrenoceptor Antagonists. , 2021, , .		0
24	Normalization of organ bath contraction data for tissue specimen size: does one approach fit all?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 243-251.	3.0	18
25	New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology. <i>Drug Metabolism and Disposition</i> , 2020, 48, 64-74.	3.3	9
26	Upregulation of Î²3-adrenoceptorsâ€”a general marker of and protective mechanism against hypoxia?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 141-146.	3.0	5
27	New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology. <i>Molecular Pharmacology</i> , 2020, 97, 49-60.	2.3	79
28	Expression and Signaling of Î²-Adrenoceptor Subtypes in the Diabetic Heart. <i>Cells</i> , 2020, 9, 2548.	4.1	6
29	A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes. <i>Cells</i> , 2020, 9, 1923.	4.1	14
30	Cardiac and Vascular Î±1-Adrenoceptors in Congestive Heart Failure: A Systematic Review. <i>Cells</i> , 2020, 9, 2412.	4.1	10
31	Î±1-adrenoceptor activity of Î²-adrenoceptor ligands â€” An expected drug property with limited clinical relevance. <i>European Journal of Pharmacology</i> , 2020, 889, 173632.	3.5	12
32	Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan® Retard) Compared with Other Formulations in Healthy Volunteers. <i>Pulmonary Therapy</i> , 2020, 6, 119-130.	2.2	3
33	New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 372, 136-147.	2.5	53
34	Impact of guideline awareness in public pharmacies on counseling of patients with acute or chronic constipation in a survey of pharmacy personnel. <i>BMC Gastroenterology</i> , 2020, 20, 191.	2.0	3
35	EDITORIAL COMMENT. <i>Urology</i> , 2020, 137, 6.	1.0	0
36	Randomized, Placebo-Controlled, Double-Blind and Open-Label Studies in the Treatment and Prevention of Acute Diarrhea With <i>Enterococcus faecium</i> SF68. <i>Frontiers in Medicine</i> , 2020, 7, 276.	2.6	6

#	ARTICLE	IF	CITATIONS
37	Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 816.	3.5	8
38	Choice of y-axis can mislead readers. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1769-1772.	3.0	2
39	Where will the next generation of medical treatments for overactive bladder syndrome come from?. <i>International Journal of Urology</i> , 2020, 27, 289-294.	1.0	15
40	Editorial: G Protein-Coupled Receptor Kinases (GRKs) and $\beta$ -Arrestins: New Insights Into Disease Regulators. <i>Frontiers in Pharmacology</i> , 2020, 10, 1654.	3.5	1
41	Do overactive bladder symptoms and their treatment-associated changes exhibit a normal distribution? Implications for analysis and reporting. <i>Neurourology and Urodynamics</i> , 2020, 39, 754-761.	1.5	13
42	Die Reproduzierbarkeitskrise: Bedrohung oder Chance für die Wissenschaft?. <i>Biologie in Unserer Zeit</i> , 2020, 50, 79-79.	0.2	0
43	Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals. <i>BMI Open Science</i> , 2020, 44, e100046.	1.7	40
44	PD33-02: IMPACT OF EARLY VS. DELAYED INITIATION OF DUTASTERIDE/TAMSULOSIN COMBINATION THERAPY IN LOWER URINARY TRACT SYMPTOMS/BENIGN PROSTATIC HYPERPLASIA (LUTS/BPH) PATIENTS WITH MODERATE TO SEVERE SYMPTOMS AT RISK FOR PROGRESSION. <i>Journal of Urology</i> , 2020, 203, e704-e705.	0.4	0
45	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 324-324.	0.4	0
46	Bladder Enlargement Correlates with Plasma Insulin, Not Glucose Levels in Fructose-Fed Rats. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0
47	Is Dipstick Urinalysis Screening Beneficial in Men with Lower Urinary Tract Symptoms?. <i>Advances in Therapy</i> , 2019, 36, 2954-2967.	2.9	1
48	Desensitization of cAMP Accumulation via Human $\beta$ -3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists. <i>Frontiers in Pharmacology</i> , 2019, 10, 596.	3.5	7
49	Cognitive and mood side effects of lower urinary tract medication. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 915-923.	2.4	22
50	Adrenoceptors: New roles for old players. <i>British Journal of Pharmacology</i> , 2019, 176, 2339-2342.	5.4	7
51	Why Are New Drugs Expensive and How Can They Stay Affordable?. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 453-466.	1.8	5
52	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2019, 176, S21-S141.	5.4	519
53	Urinary Bladder Weight and Function in a Rat Model of Mild Hyperglycemia and Its Treatment With Dapagliflozin. <i>Frontiers in Pharmacology</i> , 2019, 10, 911.	3.5	10
54	Agonist-induced desensitisation of $\beta$ -3-adrenoceptors: Where, when, and how?. <i>British Journal of Pharmacology</i> , 2019, 176, 2539-2558.	5.4	26

#	ARTICLE	IF	CITATIONS
55	β <sub>3</sub> -Adrenoceptors in the normal and diseased urinary bladder—What are the open questions?. <i>British Journal of Pharmacology</i> , 2019, 176, 2525-2538.	5.4	33
56	Cardiac β <sub>3</sub> -Adrenoceptors—A role in human pathophysiology?. <i>British Journal of Pharmacology</i> , 2019, 176, 2482-2495.	5.4	21
57	Building Robustness into Translational Research. <i>Handbook of Experimental Pharmacology</i> , 2019, 257, 163-175.	1.8	7
58	Perspectives of Pharmacology over the Past 100 Years. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 3-16.	1.8	2
59	Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging. <i>Medicinal Research Reviews</i> , 2019, 39, 1014-1052.	10.5	22
60	Adrenoceptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	13
61	Neuropeptide Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	2
62	A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin-induced rat models. <i>Neurourology and Urodynamics</i> , 2018, 37, 1212-1219.	1.5	22
63	Biased Agonism in Drug Discovery—Is It Too Soon to Choose a Path?. <i>Molecular Pharmacology</i> , 2018, 93, 259-265.	2.3	76
64	Muscarinic type-1 receptors contribute to I <sub>K,ACh</sub> in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 255, 61-68.	1.7	22
65	Lower Urinary Tract Symptoms: What's New in Medical Treatment?. <i>European Urology Focus</i> , 2018, 4, 17-24.	3.1	23
66	Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals. <i>BMJ Open Science</i> , 2018, 2, e000004.	1.7	6
67	Commentary on the <i>BJP</i> 's new statistical reporting guidelines. <i>British Journal of Pharmacology</i> , 2018, 175, 3636-3637.	5.4	10
68	A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences. <i>Neurourology and Urodynamics</i> , 2018, 37, 2346-2360.	1.5	28
69	Treatment of Bladder Pain Syndrome: One Size May Not Fit All. <i>European Urology</i> , 2018, 74, 631-632.	1.9	4
70	Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 675-694.	3.0	32
71	Re: Tamsulosin and the Risk of Dementia in Older Men with Benign Prostatic Hyperplasia. <i>European Urology</i> , 2018, 74, 522-523.	1.9	8
72	Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations. <i>BMC Pharmacology &amp; Toxicology</i> , 2018, 19, 40.	2.4	14

#	ARTICLE	IF	CITATIONS
73	Do review articles boost journal impact factors? A longitudinal analysis for five pharmacology journals. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 1033-1035.	3.0	5
74	Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>European Urology</i> , 2017, 71, 834-835.	1.9	1
75	Editorial on "β <sub>3</sub> adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study". <i>Neurourology and Urodynamics</i> , 2017, 36, 2192-2192.	1.5	0
76	Do β <sub>3</sub> -adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F859-F861.	2.7	9
77	The β <sub>3</sub> -adrenoceptor agonist mirabegron increases human atrial force through β <sub>1</sub> -adrenoceptors: an indirect mechanism?. <i>British Journal of Pharmacology</i> , 2017, 174, 2706-2715.	5.4	43
78	Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms. <i>International Journal of Clinical Practice</i> , 2017, 71, e12907.	1.7	15
79	Revised editorial guidelines for manuscripts on the pharmacology of plant extracts. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 765-766.	3.0	3
80	Denominator changes may obscure results from single-well assays: β <sub>3</sub> -adrenoceptor ligand-induced changes of cell number as example. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 761-763.	3.0	2
81	Pathophysiological Factors in the Relationship between Chronological Age and Calculated Lung Age as Detected in a Screening Setting in Community-Dwelling Subjects. <i>Frontiers in Medicine</i> , 2016, 3, 2.	2.6	3
82	β <sub>2</sub> -Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in β <sub>2</sub> -Adrenoceptor Knockout Mice. <i>Frontiers in Pharmacology</i> , 2016, 7, 118.	3.5	6
83	Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data. <i>Frontiers in Pharmacology</i> , 2016, 7, 461.	3.5	60
84	β <sub>3</sub> -Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. , 2016, 159, 66-82.		52
85	Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. , 2016, 164, 1-81.		55
86	Editorial Comment. <i>Journal of Urology</i> , 2016, 196, 1808-1808.	0.4	1
87	Cellular basis of detrusor smooth muscle contraction. <i>BJU International</i> , 2016, 117, 177-178.	2.5	3
88	How β <sub>3</sub> -adrenoceptor-selective is mirabegron?. <i>British Journal of Pharmacology</i> , 2016, 173, 429-430.	5.4	11
89	Impact of Formulation on the Pharmacokinetic Profile of Dutasteride. <i>Clinical Drug Investigation</i> , 2016, 36, 769-770.	2.2	0
90	Preclinical research strategies for newly approved drugs as reflected in early publication patterns. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 187-199.	3.0	4

#	ARTICLE	IF	CITATIONS
91	Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 815-817.	3.0	2
92	Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 201-209.	3.0	4
93	Re: A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction. European Urology, 2016, 69, 174.	1.9	2
94	Safety and tolerability of $\beta_3$ -adrenoceptor agonists in the treatment of overactive bladder syndrome – insight from transcriptome and experimental studies. Expert Opinion on Drug Safety, 2016, 15, 647-657.	2.4	42
95	Use of Antibodies in the Research on Muscarinic Receptor Subtypes. Neuromethods, 2016, , 83-94.	0.3	2
96	Reproducibility of preclinical data: one man's poison is another man's meat. Advances in Precision Medicine, 2016, 1, .	0.3	1
97	Trust me – I'm a scientist. , 2016, , 33-35.		0
98	Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers. EJNMMI Research, 2015, 5, 119.	2.5	6
99	Are blood vessels a target to treat lower urinary tract dysfunction?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 687-694.	3.0	22
100	How much potential for transient receptor potential channels in the bladder?. BJU International, 2015, 115, 350-351.	2.5	0
101	Therapeutic targets for overactive bladder other than smooth muscle. Expert Opinion on Therapeutic Targets, 2015, 19, 687-705.	3.4	20
102	Expectations and satisfaction of academic investigators in nonclinical collaboration with the pharmaceutical industry. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 613-622.	3.0	4
103	Selectivity of pharmacological tools: implications for use in cell physiology. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms. American Journal of Physiology - Cell Physiology, 2015, 308, C505-C520.	4.6	20
104	A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 801-816.	3.0	54
105	Sa1790 Comparative Clinical Studies Between Racecadotril and Loperamide or Saccharomyces Boulardii in Adult Patients With Acute Diarrhea. Gastroenterology, 2015, 148, S-333.	1.3	0
106	$\beta_3$ -Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 749-759.	3.0	18
107	Regulation of GAPDH expression by treatment with the $\beta_2$ -adrenoceptor agonist isoprenaline – is GAPDH a suitable loading control in immunoblot experiments?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1119-1120.	3.0	14
108	Synthesis and Evaluation in Rats of the Dopamine D2/3 Receptor Agonist 18F-AMC20 as a Potential Radioligand for PET. Journal of Nuclear Medicine, 2015, 56, 133-139.	5.0	6

#	ARTICLE	IF	CITATIONS
109	Therapeutic Modulation of Urinary Bladder Function: Multiple Targets at Multiple Levels. Annual Review of Pharmacology and Toxicology, 2015, 55, 269-287.	9.4	21
110	What Do Academic Investigators Want and Get from Preclinical Collaboration with the Pharmaceutical Industry?. FASEB Journal, 2015, 29, 928.10.	0.5	0
111	How significant are your data? The need for a culture shift. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 1015-1016.	3.0	6
112	Rat $\alpha_2$ -adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 1117-1127.	3.0	17
113	Bradykinin Contracts Rat Urinary Bladder Largely Independently of Phospholipase C. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 25-31.	2.5	13
114	An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material. International Journal of Clinical Practice, 2014, 68, 1074-1080.	1.7	7
115	Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors. International Journal of Molecular Imaging, 2014, 2014, 1-10.	1.3	0
116	Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors. EJNMMI Research, 2014, 4, 53.	2.5	4
117	OnabotulinumtoxinA: How Deep Will It Go?. European Urology, 2014, 65, 1125-1127.	1.9	6
118	Muscarinic receptor subtype mRNA expression in the human prostate: association with age, pathological diagnosis, prostate size, or potentially interfering medications?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 207-214.	3.0	8
119	Do $\alpha_2$ -adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 215-224.	3.0	30
120	The $\alpha_1B$ -adrenoceptor subtype mediates adrenergic vasoconstriction in mouse retinal arterioles with damaged endothelium. British Journal of Pharmacology, 2014, 171, 3858-3867.	5.4	21
121	The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. Pharmacological Reviews, 2014, 66, 222-307.	16.0	418
122	Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 480-482.	2.5	0
123	Dynamic bias and its implications for GPCR drug discovery. Nature Reviews Drug Discovery, 2014, 13, 869-869.	46.4	15
124	Cardiovascular and ocular safety of $\alpha_1$ -adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opinion on Drug Safety, 2014, 13, 1187-1197.	2.4	41
125	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 505-521.	3.0	97
126	The Odd Sibling: Features of $\alpha_3$ -Adrenoceptor Pharmacology. Molecular Pharmacology, 2014, 86, 479-484.	2.3	73



#	ARTICLE	IF	CITATIONS
127	Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability. <i>Neurourology and Urodynamics</i> , 2014, 33, 17-30.	1.5	228
128	The pharmacological rationale for combining muscarinic receptor antagonists and $\hat{1}^2$ -adrenoceptor agonists in the treatment of airway and bladder disease. <i>Current Opinion in Pharmacology</i> , 2014, 16, 31-42.	3.5	45
129	Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse <sup>®</sup> ) with those of an alleged biosimilar. <i>Frontiers in Pharmacology</i> , 2014, 5, 7.	3.5	8
130	$\hat{1}^2$ -Adrenoceptors: a drug target in ophthalmology?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 265-267.	3.0	9
131	Agonist-induced desensitization of human $\hat{1}^2$ -adrenoceptors expressed in human embryonic kidney cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 843-851.	3.0	16
132	A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists. <i>Pharmacological Reviews</i> , 2013, 65, 809-848.	16.0	233
133	Publication trends in Naunyn-Schmiedeberg's Archives of Pharmacology: focus on pharmacology in Egypt. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 929-933.	3.0	1
134	Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1098-1108.	2.4	5
135	Cross-regulation between cardiac muscarinic acetylcholine receptors and $\hat{1}^2$ -adrenoceptors: lessons for use of knock-out mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 1-3.	3.0	5
136	Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 135-154.	3.0	34
137	The new radioligand [3H]-L 748,337 differentially labels human and rat $\hat{1}^2$ -adrenoceptors. <i>European Journal of Pharmacology</i> , 2013, 720, 124-130.	3.5	23
138	Bradykinin modulates spontaneous nerve growth factor production and stretch-induced ATP release in human urothelium. <i>Pharmacological Research</i> , 2013, 70, 147-154.	7.1	25
139	Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases. <i>Pharmacological Research</i> , 2013, 74, 1-6.	7.1	24
140	Pharmacological profile of $\hat{1}^2$ -adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 177-183.	3.0	71
141	An invitation for comprehensive single-compound reviews on the pharmacological properties of newly launched drugs. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 1019-1020.	3.0	0
142	EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. <i>European Urology</i> , 2013, 64, 118-140.	1.9	990
143	Are polymorphisms of the $\hat{1}^2$ -adrenoceptor gene associated with an altered bladder function?. <i>Neurourology and Urodynamics</i> , 2013, 32, 276-280.	1.5	15
144	Editorial Comment from Dr Michel to Expression and functional role of $\hat{1}^2$ -adrenoceptors in the human ureter. <i>International Journal of Urology</i> , 2013, 20, 1015-1015.	1.0	0

#	ARTICLE	IF	CITATIONS
145	Specificity evaluation of antibodies against human $\beta_3$ -adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 875-882.	3.0	35
146	A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the $\beta_3$ -Adrenoceptor Agonist Solabegron for Overactive Bladder. <i>European Urology</i> , 2012, 62, 834-840.	1.9	96
147	A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Management—a Systematic Review and Meta-analysis. <i>European Urology</i> , 2012, 62, 877-890.	1.9	231
148	The Effect of Elective Sham Dose Escalation on the Placebo Response During an Antimuscarinic Trial for Overactive Bladder Symptoms. <i>Journal of Urology</i> , 2012, 187, 1721-1726.	0.4	6
149	A Comprehensive Review of the Pharmacodynamics, Pharmacokinetics, and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril. <i>Frontiers in Pharmacology</i> , 2012, 3, 93.	3.5	49
150	Functional investigation of $\beta_2$ -adrenoceptors in human isolated detrusor focusing on the novel selective $\beta_3$ -adrenoceptor agonist KUC-7322. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 759-767.	3.0	28
151	Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 821-825.	2.4	50
152	Expression profiling of G-protein-coupled receptors in human urothelium and related cell lines. <i>BJU International</i> , 2012, 110, E293-300.	2.5	34
153	Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. <i>BJU International</i> , 2012, 110, E422-8.	2.5	27
154	Polymorphisms in Human Muscarinic Receptor Subtype Genes. <i>Handbook of Experimental Pharmacology</i> , 2012, , 49-59.	1.8	10
155	Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa. <i>Pharmacological Research</i> , 2011, 64, 420-425.	7.1	19
156	$\beta_2$ -Adrenergic Receptor Subtypes in the Urinary Tract. <i>Handbook of Experimental Pharmacology</i> , 2011, , 307-318.	1.8	32
157	Understanding Dose Titration: Overactive Bladder Treatment With Fesoterodine as an Example. <i>European Urology Supplements</i> , 2011, 10, 8-13.	0.1	13
158	Human Urinary Bladder Strip Relaxation by the $\beta_2$ -Adrenoceptor Agonist Isoprenaline: Methodological Considerations and Effects of Gender and Age. <i>Frontiers in Pharmacology</i> , 2011, 2, 11.	3.5	22
159	A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 235-246.	2.4	152
160	Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 247-256.	2.4	32
161	Are there functional $\beta_3$ -adrenoceptors in the human heart?. <i>British Journal of Pharmacology</i> , 2011, 162, 817-822.	5.4	34
162	$\beta_2$ -Adrenoceptor agonist effects in experimental models of bladder dysfunction. , 2011, 131, 40-49.		29

#	ARTICLE	IF	CITATIONS
163	Lack of evidence that nebivolol is a $\beta_2$ -adrenoceptor agonist. <i>European Journal of Pharmacology</i> , 2011, 654, 86-91.	3.5	29
164	Desirable properties of $\beta_2$ -adrenoceptor agonists: Implications for the selection of drug development candidates. <i>European Journal of Pharmacology</i> , 2011, 657, 1-3.	3.5	10
165	Efficacy of propiverine ER with or without $\alpha_1$ -blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. <i>World Journal of Urology</i> , 2011, 29, 217-223.	2.2	21
166	The muscarinic receptor antagonist propiverine exhibits $\alpha_1$ -adrenoceptor antagonism in human prostate and porcine trigonum. <i>World Journal of Urology</i> , 2011, 29, 149-155.	2.2	14
167	Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxation. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 384, 555-563.	3.0	19
168	Which single-item measures of overactive bladder symptom treatment correlate best with patient satisfaction?. <i>Neurourology and Urodynamics</i> , 2011, 30, 510-514.	1.5	11
169	Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. <i>Neurourology and Urodynamics</i> , 2011, 30, 1227-1241.	1.5	115
170	Mechanisms of nerve growth factor release from a human urothelial cell line. <i>FASEB Journal</i> , 2011, 25, 1020.5.	0.5	0
171	Is antimuscarinic treatment of overactive bladder symptoms effective and safe in elderly patients?. <i>Aging Health</i> , 2010, 6, 595-597.	0.3	0
172	The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: $\alpha_1$ -Blockers in the Treatment of Male Voiding Dysfunction – How Do They Work and Why Do They Differ in Tolerability?. <i>Journal of Pharmacological Sciences</i> , 2010, 112, 151-157.	2.5	39
173	Tissue functions mediated by $\beta_2$ -adrenoceptors – findings and challenges. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010, 382, 103-108.	3.0	39
174	Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. <i>World Journal of Urology</i> , 2010, 28, 3-8.	2.2	29
175	The role of nocturia in the quality of life of men with lower urinary tract symptoms. <i>BJU International</i> , 2010, 105, 1141-1146.	2.5	55
176	<i>Reply</i>. <i>BJU International</i> , 2010, 105, 1017-1018.	2.5	0
177	Can [ <sup>125</sup> I]-Iodocyanopindolol Label $\beta_2$ -Adrenoceptors in Rat Urinary Bladder?. <i>Frontiers in Pharmacology</i> , 2010, 1, 128.	3.5	8
178	Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations. <i>Clinical Pharmacokinetics</i> , 2010, 49, 177-188.	3.5	55
179	Gene expression profiling of G-protein coupled receptors in human urothelial cell lines. <i>FASEB Journal</i> , 2010, 24, 773.13.	0.5	1
180	Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy. <i>Neuropsychopharmacology</i> , 2009, 34, 999-1010.	5.4	73

#	ARTICLE	IF	CITATIONS
181	Basic Mechanisms of Urgency: Preclinical and Clinical Evidence. <i>European Urology</i> , 2009, 56, 298-308.	1.9	66
182	The effect of bladder outlet obstruction on $\alpha_1$ and $\alpha_2$ adrenoceptor expression and function. <i>Neurourology and Urodynamics</i> , 2009, 28, 349-355.	1.5	42
183	Lack of specificity of commercially available antisera against muscarinic and adrenergic receptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 379, 397-402.	3.0	131
184	How reliable are G-protein-coupled receptor antibodies?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 379, 385-388.	3.0	264
185	Effect of pre-contraction on $\beta_2$ -adrenoceptor-mediated relaxation of rat urinary bladder. <i>World Journal of Urology</i> , 2009, 27, 711-5.	2.2	39
186	Basic mechanisms of urgency: roles and benefits of pharmacotherapy. <i>World Journal of Urology</i> , 2009, 27, 705-9.	2.2	28
187	Nocturia: A non-specific but important symptom of urological disease. <i>International Journal of Urology</i> , 2009, 16, 249-256.	1.0	50
188	Do gene polymorphisms alone or in combination affect the function of human $\beta_3$ adrenoceptors?. <i>British Journal of Pharmacology</i> , 2009, 156, 127-134.	5.4	41
189	Medical Expulsive Therapy for Distal Ureteral Stones. <i>Drugs</i> , 2009, 69, 677-692.	10.9	42
190	Does the Number of Previous Vaginal Deliveries Affect Overactive Bladder Symptoms and their Response to Treatment?. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, 82-87.	1.3	16
191	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. <i>Current Opinion in Urology</i> , 2009, 19, 380-394.	1.8	161
192	Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?. <i>Current Opinion in Urology</i> , 2009, 19, 13-19.	1.8	29
193	Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and $\beta_2$ -adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 377, 449-462.	3.0	139
194	Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 378, 217-224.	3.0	18
195	S1P receptor signalling and RGS proteins; expression and function in vascular smooth muscle cells and transfected CHO cells. <i>European Journal of Pharmacology</i> , 2008, 600, 1-9.	3.5	15
196	Cholinergic Innervation and Muscarinic Receptors in the Human Prostate. <i>European Urology</i> , 2008, 54, 326-334.	1.9	58
197	Physiological and pathological regulation of the autonomic control of urinary bladder contractility. , 2008, 117, 297-312.		79
198	Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine??Clinical Use. <i>Drug Safety</i> , 2008, 31, 505-514.	3.2	55

#	ARTICLE	IF	CITATIONS
199	Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1787-1796.	1.8	105
200	Agonist-induced desensitization of rat bladder relaxation by $\beta_2$ -adrenergic agonists. <i>FASEB Journal</i> , 2008, 22, 916.5.	0.5	2
201	Septic shock: A role for RGS proteins?. <i>FASEB Journal</i> , 2008, 22, 907.10.	0.5	0
202	Inhibition of sphingosine kinase induces vasoconstriction in isolated carotid arteries obtained from spontaneous hypertensive but not normotensive rats. <i>FASEB Journal</i> , 2008, 22, 1128.8.	0.5	0
203	$\beta_3$ adrenergic receptor gene polymorphisms: comparison of human with chimpanzee and Rhesus macaque. <i>FASEB Journal</i> , 2008, 22, 1134.3.	0.5	1
204	Does Phospholipase C Mediate Muscarinic Receptor-Induced Rat Urinary Bladder Contraction?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 998-1002.	2.5	30
205	Ligand-Directed Signaling: 50 Ways to Find a Lover: Fig. 1.. <i>Molecular Pharmacology</i> , 2007, 72, 1097-1099.	2.3	34
206	Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 994-1005.	2.6	151
207	Vascular effects of sphingolipids. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2007, 96, 44-48.	1.5	33
208	Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. <i>Neurourology and Urodynamics</i> , 2007, 26, 190-195.	1.5	31
209	Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?. <i>BJU International</i> , 2007, 99, 749-752.	2.5	140
210	Tools to study $\beta_3$ -adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 374, 385-398.	3.0	90
211	Pitfalls in the normalization of real-time polymerase chain reaction data. <i>Basic Research in Cardiology</i> , 2007, 102, 195-197.	5.9	60
212	Although the phosphodiesterase inhibitors have revolutionised the treatment of ED, postoperative ED due to nerve damage remains a therapeutic challenge. <i>European Urology</i> , 2007, 52, 580-1.	1.9	2
213	Effects of $\beta_1$ -Adrenoceptor Antagonists on Male Sexual Function. <i>Drugs</i> , 2006, 66, 287-301.	10.9	119
214	Rho kinase: a target for treating urinary bladder dysfunction?. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 492-497.	8.7	90
215	$\beta_1$ , $\beta_2$ -and $\beta_3$ -adrenoceptors in the urinary bladder, urethra and prostate. <i>British Journal of Pharmacology</i> , 2006, 147, S88-119.	5.4	386
216	In vivo studies on the effects of $\beta_1$ -adrenoceptor antagonists on pupil diameter and urethral tone in rabbits. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006, 372, 346-353.	3.0	37

#	ARTICLE	IF	CITATIONS
217	An anthology from Naunyn-Schmiedeberg's Archives of Pharmacology. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 139-139.	3.0	0
218	Transient receptor potential (TRP) channels as drug targets. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 271-272.	3.0	1
219	Effects of gender, age and hypertension on $\hat{I}^2$ -adrenergic receptor function in rat urinary bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 300-309.	3.0	56
220	How valid are animal models to evaluate treatments for pulmonary hypertension?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 391-400.	3.0	64
221	Comparison of three radioligands for the labelling of human $\hat{I}^2$ -adrenoceptor subtypes. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 99-105.	3.0	46
222	Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 79-85.	3.0	44
223	Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS <sup>®</sup> ) and Alfuzosin Prolonged Release (XL). European Urology, 2006, 49, 501-509.	1.9	20
224	Re: Tatemichi S, Tomiyama Y, Maruyama I, Kobayashi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. 2006. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourol Urodynam 25:792-799.. Neurourology and Urodynamics, 2006, 25, 800-801.	1.5	5
225	Sphingosine Kinase-Dependent Activation of Endothelial Nitric Oxide Synthase by Angiotensin II. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2043-2048.	2.4	42
226	Cyclic AMP-dependent and Epac-mediated Activation of R-Ras by G Protein-coupled Receptors Leads to Phospholipase D Stimulation. Journal of Biological Chemistry, 2006, 281, 21837-21847.	3.4	68
227	Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU International, 2005, 95, 19-28.	2.5	52
228	Role of muscarinic receptor antagonists in urgency and nocturia. BJU International, 2005, 96, 37-42.	2.5	36
229	Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder. European Urology, 2005, 48, 110-115.	1.9	43
230	Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 372, 71-78.	3.0	54
231	Duloxetine in the Treatment of Stress Urinary Incontinence. Women's Health, 2005, 1, 345-358.	1.5	17
232	Does Cyclic AMP Mediate Rat Urinary Bladder Relaxation by Isoproterenol?. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 260-267.	2.5	70
233	The Neuro-Urological Connection. European Urology Supplements, 2005, 4, 18-28.	0.1	28
234	The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS <sup>®</sup> ). European Urology Supplements, 2005, 4, 15-24.	0.1	55

#	ARTICLE	IF	CITATIONS
235	Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects. <i>European Urology Supplements</i> , 2005, 4, 9-14.	0.1	28
236	Comparison of Vascular $\alpha_1$ -Adrenoceptor Antagonism of Tamsulosin in Oral Controlled Absorption System (OCAS) and Modified Release (MR) Formulations. <i>European Urology Supplements</i> , 2005, 4, 45-52.	0.1	24
237	Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation. <i>European Urology Supplements</i> , 2005, 4, 53-60.	0.1	29
238	A ROLE FOR MUSCARINIC RECEPTORS OR RHO-KINASE IN HYPERTENSION ASSOCIATED RAT BLADDER DYSFUNCTION?. <i>Journal of Urology</i> , 2005, 173, 2178-2181.	0.4	34
239	Signal Transduction Underlying Carbachol-Induced Contraction of Human Urinary Bladder. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 1148-1153.	2.5	152
240	Signal Transduction Underlying Carbachol-Induced Contraction of Rat Urinary Bladder. I. Phospholipases and $Ca^{2+}$ Sources. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 47-53.	2.5	76
241	Small and intermediate conductance $Ca^{2+}$ -activated $K^{+}$ channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 369, 602-615.	3.0	112
242	Efficacy and safety of tamsulosin in the treatment of urological diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 151-160.	1.8	23
243	DOES CONCOMITANT STRESS INCONTINENCE ALTER THE EFFICACY OF TOLTERODINE IN PATIENTS WITH OVERACTIVE BLADDER?. <i>Journal of Urology</i> , 2004, 172, 601-604.	0.4	25
244	ASSOCIATION OF HYPERTENSION WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 2004, 172, 1390-1393.	0.4	108
245	Safety of Telmisartan in Patients with Arterial Hypertension. <i>Drug Safety</i> , 2004, 27, 335-344.	3.2	53
246	Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3 receptors?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2003, 367, 524-531.	3.0	59
247	Differential agonist-induced regulation of human M2 and M3 muscarinic receptors. <i>Biochemical Pharmacology</i> , 2003, 66, 2099-2105.	4.4	13
248	Receptor gene polymorphisms: lessons on functional relevance from the $\alpha_1$ -adrenoceptor. <i>British Journal of Pharmacology</i> , 2003, 138, 279-282.	5.4	18
249	A Benefit-Risk Assessment of Extended-Release Oxybutynin. <i>Drug Safety</i> , 2002, 25, 867-876.	3.2	29
250	Does Gender or Age Affect the Efficacy and Safety of Tolterodine?. <i>Journal of Urology</i> , 2002, 168, 1027-1031.	0.4	94
251	An Extract From the Bark of <i>Aspidosperma Quebracho Blanco</i> Binds to Human Penile $\alpha_1$ -Adrenoceptors. <i>Journal of Urology</i> , 2002, 168, 160-163.	0.4	16
252	Prevalence and Physician Awareness of Symptoms of Urinary Bladder Dysfunction. <i>European Urology</i> , 2002, 41, 234-239.	1.9	81

#	ARTICLE	IF	CITATIONS
253	Does gender or age affect the efficacy and safety of tolterodine?. Journal of Urology, 2002, 168, 1027-31.	0.4	28
254	Limited signal transduction repertoire of human Y5 neuropeptide Y receptors expressed in HEC-1B cells. Peptides, 2001, 22, 387-394.	2.4	18
255	A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster $\alpha_1B$ -adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 34-39.	3.0	15
256	Modulation of noradrenaline-induced microvascular constriction by protein kinase inhibitors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 57-65.	3.0	15
257	Mitogen-activated protein kinases in the heart. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 245-266.	3.0	109
258	Nifedipine inhibits sphingosine-1-phosphate-induced renovascular contraction in vitro and in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364, 179-182.	3.0	24
259	Do saw palmetto extracts block human $\alpha_1$ -adrenoceptor subtypes in vivo?. Prostate, 2001, 46, 226-232.	2.3	23
260	Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats. British Journal of Pharmacology, 2001, 132, 1925-1933.	5.4	36
261	Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. British Journal of Pharmacology, 2000, 130, 1871-1877.	5.4	95
262	Treatment Satisfaction of Patients with Lower Urinary Tract Symptoms: Randomised Controlled Trials vs. Real Life Practice. European Urology, 2000, 38, 40-47.	1.9	29
263	$\alpha_1$ -Adrenoceptor Subtypes Differentially Couple to Growth Promotion and Inhibition in Chinese Hamster Ovary Cells. Biochemical and Biophysical Research Communications, 2000, 272, 906-911.	2.1	48
264	EFFECT OF DIABETES ON LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2000, 163, 1725-1729.	0.4	154
265	Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretion. Canadian Journal of Physiology and Pharmacology, 2000, 78, 93-99.	1.4	11
266	Differential vascular $\alpha_1$ -adrenoceptor antagonism by tamsulosin and terazosin. British Journal of Clinical Pharmacology, 1999, 47, 67-74.	2.4	24
267	Saw palmetto extracts potently and noncompetitively inhibit human $\alpha_1$ -adrenoceptors in vitro. , 1999, 38, 208-215.		84
268	Saw palmetto extracts potently and noncompetitively inhibit human $\alpha_1$ -adrenoceptors in vitro. Prostate, 1999, 38, 208-215.	2.3	6
269	Possible mechanism of the negative inotropic effect of $\alpha_1$ -adrenoceptor agonists in rat isolated left atria after exposure to free radicals. British Journal of Pharmacology, 1998, 123, 952-958.	5.4	8
270	Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation. Urological Research, 1998, 26, 149-154.	1.5	44



#	ARTICLE	IF	CITATIONS
271	Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. British Journal of Clinical Pharmacology, 1998, 45, 49-55.	2.4	46
272	TAMSULOSIN TREATMENT OF 19,365 PATIENTS WITH LOWER URINARY TRACT SYMPTOMS: DOES CO-MORBIDITY ALTER TOLERABILITY?. Journal of Urology, 1998, 160, 784-791.	0.4	99
273	Neuropeptide Y Lowers Blood Glucose in Anaesthetized Rats via a Y5Receptor Subtype. Endocrinology, 1998, 139, 3018-3021.	2.8	13
274	Bradykinin may be involved in neuropeptide Y-induced diuresis, natriuresis, and calciuresis. American Journal of Physiology - Renal Physiology, 1998, 275, F502-F509.	2.7	5
275	TAMSULOSIN TREATMENT OF 19,365 PATIENTS WITH LOWER URINARY TRACT SYMPTOMS. Journal of Urology, 1998, 160, 784-791.	0.4	45
276	Tocolytic Therapy with Fenoterol Induces Selective Down-Regulation of $\beta_2$ -Adrenergic Receptors in Human Myometrium. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1235-1242.	3.6	36
277	Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y. British Journal of Pharmacology, 1997, 120, 1335-1343.	5.4	49
278	Is $\beta_1$ -adrenoceptor protein detectable in rat tissues?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 355, 438-446.	3.0	77
279	Prejunctional Neuropeptide Y Receptors in Human Kidney and Atrium. Journal of Cardiovascular Pharmacology, 1997, 29, 656-661.	1.9	28
280	Comparison of guinea pig, bovine and rat $\beta_1$ -adrenoceptor subtypes. British Journal of Pharmacology, 1996, 117, 703-711.	5.4	9
281	Endothelin-induced inositol phosphate formation in rat kidney. Studies on receptor subtypes, G-proteins and regulation during ontogenesis. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 572-8.	3.0	7
282	Differential calcium signalling by m2 and m3 muscarinic acetylcholine receptors in a single cell type. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 352, 469-476.	3.0	32
283	Rapid desensitization of adrenaline- and neuropeptide Y-stimulated $Ca^{2+}$ mobilization in HEL cells. British Journal of Pharmacology, 1994, 112, 499-504.	5.4	16
284	Radioligand binding studies of $\beta_1$ -adrenoceptor subtypes in rat heart. British Journal of Pharmacology, 1994, 111, 533-538.	5.4	53
285	Functional studies on $\beta_1$ -adrenoceptor subtypes mediating inotropic effects in rat right ventricle. British Journal of Pharmacology, 1994, 111, 539-546.	5.4	35
286	Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 347-352.	3.0	59
287	Spare Receptors for $\beta_2$ -Adrenoceptor-Mediated Positive Inotropic Effects of Catecholamines in the Human Heart. Journal of Cardiovascular Pharmacology, 1992, 19, 222-232.	1.9	81
288	Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a non-peptide antagonist. British Journal of Pharmacology, 1992, 105, 71-76.	5.4	33

#	ARTICLE	IF	CITATIONS
289	NPY and carbachol raise Ca <sup>2+</sup> in SK-N-MC cells by three different mechanisms. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1992, 345, 370-4.	3.0	14
290	Cyclic AMP counteracts mitogen-induced inositol phosphate generation and increases in intracellular Ca <sup>2+</sup> concentrations in human lymphocytes. <i>British Journal of Pharmacology</i> , 1991, 103, 1288-1294.	5.4	39
291	Decreased myometrial $\beta_2$ -adrenoceptors in women receiving $\beta_2$ -adrenergic tocolytic therapy: Correlation with lymphocyte $\beta_2$ -adrenoceptors. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 1-8.	4.7	58
292	Elevation of plasma neuropeptide Y levels in congestive heart failure. <i>American Journal of Medicine</i> , 1989, 86, 43-48.	1.5	117
293	Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. <i>Biochemical Pharmacology</i> , 1987, 36, 3175-3180.	4.4	51
294	Competition by monophenolic estrogens and catecholestrogens for high-affinity uptake of [3H]( $\alpha$ )-norepinephrine into synaptosomes from rat cerebral cortex and hypothalamus. <i>Brain Research</i> , 1983, 277, 163-168.	2.2	36
295	Impact of the Neck and/or Shoulder Pain on Self-reported Headache Treatment Responses – Results From a Pharmacy-Based Patient Survey. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	4